جستجوی مقالات مرتبط با کلیدواژه « potassium citrate » در نشریات گروه « پزشکی »

Considering potassium citrate ability to induce urine alkalization, it may be useful in the treatment and prevention of renal stone formation. The aim of this study was to evaluate the potassium citrate preventive effect on recurrence and also expulsion of calcium oxalate renal stones residual fragment. The study was made on 96 adult patients who referred to Shahid Faghihi hospital affiliated to Shiraz University of Medical Sciences and underwent surgical intervention with detected and cleared calcium oxalate renal stones (more than 60% of stones component). The patients had no urinary tract infection or urogenital anomalies. Four weeks following treatment of urolithiasis, patients cleared from the renal stones (n=58) and patients with urinary residual stones (n=38) were divided to two groups based on age and gender. One sub-group received 40 mEq of oral potassium citrate daily for one year while the other observed. All 4 sub-groups encouraged to high fluid intake with low salt, low oxalate diet. A significant difference in recurrence rate of renal stone was seen in patients of untreated sub-group (25.86%) with treated sub-group (1.72%) in stone free group. In the patients with residual urinary fragments, a significant decrease in stone fragments in treated subgroup (72.22%) and untreated sub-group (33.33%) was reported. The findings of this study showed that administration of potassium citrate led to significantly declined recurrence rate of calcium oxalate renal stone.Also it has a good expulsive effect on residual fragments.

To assess the tolerability of Potassium Citrate (KCit) tablets in patients with kidney stones that were not able to use the powder form of this drug due to unfavorable salty taste and /or gastrointestinal complications.
Twenty-three stone formers, with intolerance to potassium citrate powder form, which had referred to Labbafinejad stone preventive clinic in 2015, were included in this study. All of the patients took two potassium citrate tablets (10 meq), three times a day for two weeks. Spot urine samples and the 24-hour urine collections were performed before and after KCit therapy. In addition, a visual analog taste scale was completed to gauge the taste and palatability of the KCit tablets in comparison with the powder form.
All of the patients claimed that they consumed the tablets as prescribed. The urine pH (5.7 ± 0.6 to 6.1 ± 0.8, p = 0.006), 24-hour citrate (235.8 ± 190.2 to 482.5 ± 323.2, p = 0.0002) and potassium (45.25 ± 22.5 to 75.27 ± 37, p = 0.002) were significantly higher after the treatment. In addition, the mean visual analog scale score was significantly improved in KCit therapy with tablet form versus to powder form of the drug (good vs. terrible score).
Oral tolerance of KCit therapy is improved with the use of Potassium Citrate tablet, with beneficial effects on 24-hour urine citrate, potassium, and pH.

Potassium citrate (K‑Cit) is one of the therapeutic solutions broadly used in patients with urolithiasis. However, recent studies have shown that it is not so effective. Therefore, the goal of our study was to evaluate the effect of a combination of K‑Cit ‑ MgCl2 oral supplements, on urinary stone size.

This study was performed on 70 asymptomatic urolithiasis cases. The supplements included K‑Cit and magnesium chloride (MgCl2 ), purchased from (Merck Company, Germany). The patients were randomly divided into two groups. The urinary stone size was measured in the control group after prescribing K‑Cit alone and the treated group with combination of K‑Cit and MgCl2 for 4 weeks by ultrasonography and also urinary parameter was measured in each groups.

The mean age of patients was 16.26 ± 5.70 years. Hyperoxaluria and hypercalciuria were seen in 70% and 52% of patients, respectively. Initially, the mean urinary stone size was measured in each groups and there is not any significant different. However, we find a significant decrease in urinary stone size in group which is treated with combination of K‑Cit and MgCl2 for 4 weeks in comparison with control group treated with K‑Cit alone in the same duration of therapeutic course (5.1 ± 0.8 vs. 2.5 ± 1.2, P < 0.05). All ultrasonography were performed by one radiologist and device.

Our results suggested that a combination of K‑Cit and MgCl2 chloride is more effective on decreasing urinary stone size than K‑Cit alone.

The aim of this study was to design and formulation of potassium citrate effervescent tablet for reduction of calcium oxalate and urate kidney stones in patients suffering from kidney stones. In this study, 13 formulations were prepared from potassium citrate and effervescent base in different concentration. The flowability of powders and granules was studied. Then effervescent tablets were prepared by direct compression, fusion and wet granulation methods. The prepared tablets were evaluated for hardness, friability, effervescent time, pH, content uniformity. To amend taste of formulations, different flavoring agents were used and then panel test was done by using Latin Square method by 30 volunteers. Formulations obtained from direct compression and fusion methods had good flow but low hardness. Wet granulation improves flowability and other physicochemical properties such as acceptable hardness, effervescence time ≤3 minutes, pH<6, friability < 1%, water percentage < 0.5% and accurate content uniformity. In panel test, both of combination flavors; (orange - lemon) and (strawberry - raspberry) had good acceptability. The prepared tablets by wet granulation method using PVP solution had more tablet hardness. It is a reproducible process and suitable to produce granules that are compressed into effervescent tablets due to larger agglomerates.

Potassium citrate (K‑Cit) is one of the medications widely used in patients with urolithiasis. However, in some cases with calcium oxalate (CaOx) urolithiasis, the significant response to alkaline therapy with K‑Cit alone does not occur. There is scarce published data on the effect of magnesium chloride (Mg‑Cl2) on urolithiasis in pediatric patients. This study aimed to evaluate the effect of a combination of K‑Cit ‑ MgCl2 as oral supplements on urinary parameters in children with CaOx urolithiasis. This study was conducted on 24 children with CaOx urolithiasis supplements included potassium citrate (K‑Cit) and magnesium chloride (Mg‑Cl2). The serum and urinary electrolytes were measured before (phase 0) and after prescribing K‑Cit alone (phase 1) and a combination of K‑Cit and Mg‑Cl2 (phase 2). Each phase of therapy lasted for 4 weeks. The mean age of patients was 6.46 ± 2.7 years. Hyperoxaluria and hypercalciuria were seen in 66% and 41% of patients, respectively. Serum magnesium increased significantly during phase 2 comparing with phase 0. Urinary citrate level was significantly higher in phase 1 and 2 in comparison with phase 0, P < 0.05. In addition, urinary oxalate excretion was significantly diminished in phase 2 comparing with phase 0 and 1, P < 0.05. Soft stool was reported by 4 patients, but not severe enough to discontinue medications. These results suggested that a combination of K‑Cit and Mg‑Cl2 chloride is more effective on decreasing urinary oxalate excretion than K‑Cit alone. The Iranian Clinical Trial registration number IRCT138707091282N1.